How to treat residual inflammatory risk?Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Brigham and Women's Hospital, Boston, MA, USA
In patients with elevated LDL-c and CRP, adding another lipid-lowering therapy may not adequately lower CV risk. Targeting residual inflammatory risk may be an effective strategy for secondary prevention. Two large, ongoing studies evaluate whether reducing inflammation, without lowering LDL-c, can reduce CV events.
Vascular Biology Working Group Meeting at ACC 2016, Chicago, IL, USA
Faculty & Disclosures
Paul Ridker, MD - Director of the Center for Cardiovascular Disease Prevention, Eugene Braunwald Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA